Canaccord Genuity Reiterates a 'Buy' on Edwards Lifesciences (EW); Latest Data Gives Edge to Sapien

Canaccord Genuity reiterates a 'Buy' on Edwards Lifesciences (NYSE: EW) price target of $123.00.

Analyst, Jason Mills, said, "A German registry presented at the ESC meeting last week showed SAPIEN to have lower rates of paravalvular leak (PVL) and permanent pacemaker (PPM) implantation vs. CoreValve. While CoreValve’s higher PPM rate is well known, the higher incidence of mild PVL is new information. As a reminder, two-year PARTNER Cohort A data showed that mild aortic regurgitation (AR) is associated with increased mortality. SAPIEN’s better performance with regard to PVL in this registry is positive for EW, in our view, as European centers “cross-pollinate” with both valves on shelves."

For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.

Shares of Edwards Lifesciences closed at $102.11 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
• Walmart (WMT) PT Lowered to $126 at BofA Securities
• NetEase.com (NTES) PT Raised to $168 at Goldman Sachs